Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. - Wikidata - awgldk - TriplyDB

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

http://www.wikidata.org/entity/Q34744012

about

Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance.D-Alanine-Controlled Transient Intestinal Mono-Colonization with Non-Laboratory-Adapted Commensal E. coli Strain HS.Salmonella-induced mucosal lectin RegIIIβ kills competing gut microbiota Gut Microbiota Species Can Provoke both Inflammatory and Tolerogenic Immune Responses in Human Dendritic Cells Mediated by Retinoic Acid Receptor Alpha Ligation.Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.Lactobacillus plantarum prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal permeability.Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.Direct injection of functional single-domain antibodies from E. coli into human cells.Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.Fecal microbiota transplantation in metabolic syndrome: History, present and future.Comparative metabolomics and structural characterizations illuminate colibactin pathway-dependent small molecules.Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science Intestinal inflammation responds to microbial tissue load independent of pathogen/non-pathogen discrimination.Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine.Gut symbionts from distinct hosts exhibit genotoxic activity via divergent colibactin biosynthesis pathways.Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health.Programmable probiotics for detection of cancer in urine.Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity.Minocycline: far beyond an antibiotic.Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron.Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis Therapeutic effects of four strains of probiotics on experimental colitis in mice Human β-defensin 2 induces extracellular accumulation of adenosine in Escherichia coli F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917.A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.Persistence of colicinogenic Escherichia coli in the mouse gastrointestinal tract.Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications.Uropathogenic Escherichia coli Suppresses the host inflammatory response via pathogenicity island genes sisA and sisB.Effects of Escherichia coli Nissle 1917 and Ciprofloxacin on small intestinal epithelial cell mRNA expression in the neonatal piglet model of human rotavirus infection pMPES: A Modular Peptide Expression System for the Delivery of Antimicrobial Peptides to the Site of Gastrointestinal Infections Using Probiotics.Engineering Escherichia coli for light-activated cytolysis of mammalian cells.A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis.Investigational agents for Crohn's disease.Escherichia coli Nissle 1917 (Mutaflor): new insights into an old probiotic bacterium.

P2860

Q26746916-38F55D69-D8A2-4129-9A07-AF77F09F0A77 Q26748672-763929D3-A34C-4646-90E0-0B50F1729023 Q27003192-18466225-F580-4173-88C8-86FCC546D4F0 Q27304899-8BBE2989-00E5-44B0-9C19-DCC7CEE96E4D Q27316775-A8CB53FE-8DC7-49A0-906D-2CF818256B6A Q28504981-10B394E8-7D10-4460-A01A-105549690F3C Q33571508-A37ABF88-AEC2-42D0-9088-B81003E8D87B Q33571968-10D209FA-5DF2-417F-93E6-64402F85E7F2 Q33613698-88DD6337-1F20-45D3-9FE3-BAC4B76E2F69 Q33724207-F9BC8230-BB4C-4881-9D3C-EBA7D87F4DDD Q33775617-C842B565-EB3E-482C-93FA-3B3DAF72603F Q33781683-B27EB5F2-E180-4F8E-A6E2-7D522A535C66 Q33815397-8E2F3F4D-B770-42A2-B6D1-BDACB2F64CCA Q33821397-F8DBF8F0-3138-44CF-9445-FC2FE740166C Q33879227-20D8E5A6-1130-442A-AD4E-D185C5B85078 Q34162963-E5416AC6-004F-48AE-A6B7-34E0A216F1DA Q34269047-6645DE20-22E9-40DA-9215-53C9D4C1371E Q34407175-6CFE1DD9-5500-4B0E-ACD6-392BE25C8704 Q34562484-DB263CA3-903C-42CA-BA3E-F0F9B1176F48 Q35024032-0724E603-628B-469D-AD11-A2F092C46D53 Q35581546-C6BB6748-0927-4ACF-A415-7AC97C96EAF6 Q35879638-BAFFF67B-A41D-442A-A03A-2AF0033F7454 Q36174448-84B969C8-8DE6-430D-BC59-5FD042C01019 Q36392065-06C9DB21-0B96-4CEE-8919-2F0F67F6F3E3 Q36836358-CB56C8B3-E5E7-4514-8096-43AB5E897282 Q37118020-CB2AB359-2E44-4C62-BAF1-3860BB368D87 Q37118873-FC03D89D-C8F0-4DC4-B288-FAFFEC315AEF Q37122235-D8745286-EBD3-4A1A-911B-F491E6CBA57E Q37123995-177CC6C1-18A1-4A05-AA24-86CA59BA1EBC Q37321805-7825598F-B921-4C28-A26E-1FFDE4294587 Q37332655-8E858FFB-C3E4-4C79-B95B-235F0C826A64 Q37341276-A8894BD3-D364-4363-901E-F07738A3209F Q37396622-8616D29D-113E-40D5-B5A8-0C15FD20212B Q37451184-1D9BB02A-4526-4BF0-9443-9CD9DB65FE89 Q37498366-40516A8D-56C8-4F84-9225-93D83B398663 Q37542328-B1BF2C37-0E0F-448F-BF9C-1802DF3827AE Q37605074-E3B7CAD4-4063-4D22-9B99-DFA9D2F541A6 Q37690960-94787644-C96E-40BB-A451-A082724DA021 Q37788217-6079F150-6A62-4F6C-A963-9EB180DBF35D Q37969596-BC20DE35-24BC-4128-834C-2F02D77DBBE7

P2860

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

http://www.wikidata.org/entity/Q34744012

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@ast

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@en

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@nl

type

label

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@ast

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@en

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@nl

prefLabel

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@ast

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@en

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@nl

P1433

Q34744012-C186D50F-489A-4FB2-8CA7-D3A41A8C2774

P1476

Q34744012-7E82045C-ADD5-4E3D-98F8-AB4A8B3B2EEA

P2093

Q34744012-653C937C-626C-4A05-A7E9-51B161D0996C

P2860

Q34744012-004E05D5-4F99-4EAB-B0B8-B9F71F301C1F

Q34744012-02B78C8B-05B3-4EFE-8592-263887054C5F

Q34744012-0440C873-686C-4F18-8224-B42167196930

Q34744012-057359DA-9F17-49D3-B7FB-48A5459C4E3A

Q34744012-0EE96388-04A2-4758-B345-71CB9DD8951E

Q34744012-14FC17BB-D0D6-46A1-B21B-E290DDD29F07

Q34744012-1614C7CF-A34E-4D7B-838D-F8023F3C2BE0

Q34744012-1E646C49-8994-4EE5-ACD7-7FC3A83C311C

Q34744012-1F229EB7-0623-4097-9DF1-5DCF7113E707

Q34744012-290CF8F4-5885-409C-B8FD-4500154E5C43

P304

Q34744012-E8DA3011-44B0-4D52-A415-8EDE93EE338E

P31

Q34744012-226F4DEC-4FE0-4361-9BA2-48BCCFAB6B82

P356

Q34744012-ABB18002-9E53-4D62-9ABE-544AA1BE1788

P433

Q34744012-1CE43F82-5B9A-48CC-B971-E57416A08B32

P478

Q34744012-FD6538D7-B02C-4364-A571-48911161B73D

P577

Q34744012-15BE4D9F-3A2F-4769-965D-C85FF4EE2FD6

P698

Q34744012-FEB982A9-2340-47A8-9994-83B881A272FF

P921

Q34744012-10E24995-953E-4AB7-A75B-B0BF07C0A129

Q34744012-55EB391D-5CFF-46F7-9659-EE58C6569EE3

Q34744012-BAEAFA63-FF2C-474A-B071-8CED6071B4BC

P356

P1433

Inflammatory Bowel Diseases

P1476

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

@en

P2093

Michael Schultz

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917

Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data.

[Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey].

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells

Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis.

The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers.

P304

1012-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20377

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18240278

http://www.w3.org/2001/XMLSchema#string

P921

Escherichia coli

inflammatory bowel diseases